Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Technetium Tc-99m Sestamibi

Phase 1Radiopharmaceutical

MM.D. Anderson Cancer Center

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Estrogen Receptor NegativeActive, not recruiting

Estrogen Receptor NegativePhase 1

Active, not recruiting

Timeline

Expected Milestones

Q2 2028

Phase 1Active, not recruiting

Estrogen Receptor Negative

NCT02744053

Clinical

Trials by Indication[1]

Estrogen Receptor Negative1 trial

Multimodality Breast Imaging for the Assessment of Tumor Response to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer Patients

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT02744053·96 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Technetium Tc-99m Sestamibi. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Technetium Tc-99m Sestamibi compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Technetium Tc-99m Sestamibi. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — M.D. Anderson Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Radiopharmaceutical[2]
Highest Phase: Phase 1[1]
Company: MM.D. Anderson Cancer Center

Related News